Table 3.
PRLR single-nucleotide polymorphisms associated with breast cancer in the Polish Breast Cancer Study, by menopausal statusa
| Single-nucleotide polymorphism | Case | Control | OR (95% CI)b | P | Mean prolactin in sampled controlsc, ng/mL (95% CI) | P trend |
|---|---|---|---|---|---|---|
| All subjects | ||||||
| PRLR rs249537 | ||||||
| CC | 1,331 | 1,540 | Referent | |||
| CT | 388 | 400 | 1.12 (0.96-1.32) | 0.15 | ||
| TT | 19 | 10 | 2.19 (1.02-4.73) | 0.05 | ||
| T vs. C | 1.17 (1.01-1.35) | 0.04 | ||||
| PRLR rs13436213 | ||||||
| GG | 698 | 829 | Referent | |||
| AG | 814 | 885 | 1.09 (0.95-1.26) | 0.21 | ||
| AA | 237 | 238 | 1.18 (0.96-1.46) | 0.11 | ||
| A vs. G | 1.09 (0.99-1.20) | 0.08 | ||||
| PRLR rs7718468 | ||||||
| TT | 739 | 895 | Referent | |||
| CT | 771 | 831 | 1.12 (0.98-1.29) | 0.10 | ||
| CC | 214 | 209 | 1.24 (1.00-1.54) | 0.05 | ||
| C vs. T | 1.12 (1.01-1.23) | 0.02 | ||||
| Premenopausal | ||||||
| PRLR rs249537 | ||||||
| CC | 351 | 492 | Referent | 5.50 (4.05-7.47) | ||
| CT | 104 | 122 | 1.19 (0.88-1.59) | 0.26 | 5.51 (3.86-7.87) | |
| TT | 12 | 2 | 8.42 (1.89-37.9) | 0.01 | 3.83 (1.36-10.82) | |
| T vs. C | 1.39 (1.07-1.80) | 0.01 | 0.84 | |||
| PRLR rs13436213 | ||||||
| GG | 196 | 269 | Referent | 5.35 (3.90-7.33) | ||
| AG | 220 | 265 | 1.14 (0.88-1.48) | 0.32 | 5.30 (3.83-7.32) | |
| AA | 55 | 82 | 0.92 (0.62-1.36) | 0.67 | 5.40 (3.75-7.80) | |
| A vs. G | 1.01 (0.85-1.20) | 0.92 | 0.98 | |||
| PRLR rs7718468 | ||||||
| TT | 204 | 286 | Referent | 5.79 (4.22-7.94) | ||
| CT | 209 | 250 | 1.18 (0.91-1.53) | 0.21 | 5.46 (3.90-7.64) | |
| CC | 50 | 72 | 0.97 (0.65-1.46) | 0.90 | 5.21 (3.6-7.54) | |
| C vs. T | 1.05 (0.87-1.25) | 0.63 | 0.31 | |||
| Postmenopausal | ||||||
| PRLR rs249537 | ||||||
| CC | 980 | 1,048 | Referent | 6.36 (5.01-8.07) | ||
| CT | 284 | 278 | 1.11 (0.92-1.34) | 0.28 | 6.45 (4.99-8.33) | |
| TT | 7 | 8 | 0.94 (0.34-2.61) | 0.90 | 6.42 (3.64-11.32) | |
| T vs. C | 1.09 (0.92-1.31) | 0.33 | 0.81 | |||
| PRLR rs13436213 | ||||||
| GG | 502 | 560 | Referent | 6.29 (4.97-7.95) | ||
| AG | 594 | 620 | 1.07 (0.91-1.27) | 0.40 | 6.52 (5.15-8.25) | |
| AA | 182 | 156 | 1.32 (1.03-1.68) | 0.03 | 6.48 (5.01-8.39) | |
| A vs. G | 1.13 (1.01-1.26) | 0.04 | 0.48 | |||
| PRLR rs7718468 | ||||||
| TT | 535 | 609 | Referent | 6.47 (5.09-8.22) | ||
| CT | 562 | 581 | 1.11 (0.94-1.31) | 0.21 | 6.86 (5.39-8.74) | |
| CC | 164 | 137 | 1.39 (1.07-1.79) | 0.01 | 6.41 (4.89-8.4) | |
| C vs. T | 1.16 (1.03-1.30) | 0.01 | 0.56 |
aA complete list of single-nucleotide polymorphism associations with breast cancer risk can be found in Supplementary table S2 in Additional file 1. bOdds ratio (OR) and confidence interval (CI) adjusted for age and study site. cAdjusted for age, study site, time of blood collection, and time since last period (premenopausal only). PRLR, prolactin receptor (gene).